Evidence map›Paper›PMID 32915500›Full record

ArticleJournal of clinical laboratory analysis2020

A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis.

Siyuan Tian, Yansheng Liu, Keshuai Sun, Xia Zhou, Shuoyi Ma, Miao Zhang, Xinmin Zhou, Lu Wang, Ying Han

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Risk Stratification in Primary Biliary Cholangitis.Journal of clinical medicine · 2023
    Review
  5. Machine learning prediction model for treatment responders in patients with primary biliary cholangitis.JGH open : an open access journal of gastroenterology and hepatology · 2023
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Siyuan TianInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Yansheng LiuInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Keshuai SunInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Xia ZhouInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Shuoyi MaInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Miao ZhangInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Xinmin ZhouInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Lu WangInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Ying HanInstitute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.ORCID https://orcid.org/0000-0003-3046-9507
Xijing Hospital · CN

Funding

China Postdoctoral Science Foundation 2018M643871International Cooperation and Exchange of the National Natural Science Foundation of China 81820108005National Natural Science Foundation of China 81770569National Natural Science Foundation of China 81870421Postdoctoral Science Foundation of Shaanxi Province 2018BSHYDZZ74
6 · The paper itself

Abstract

backgroundUrsodeoxycholic acid (UDCA) has been widely recommended as the first-line drug for primary biliary cholangitis (PBC) in the current guidelines. However, its therapeutic effects are poor in nearly one-third of patients. The early identification and intervention of these patients is crucial for delaying disease progression. Therefore, we explored risk factors for inadequate biochemical response and constructed a nomogram to predict the potential risk.

methodsWe enrolled 356 patients and randomly divided them into training (70%) and validation groups (30%). We defined inadequate biochemical response as the study endpoint. Logistic analysis was used to identify the independent predictors of poor biochemical response. Based on these factors, a predictive nomogram was finally constructed. Then, discrimination and calibration were evaluated by internal validation. Additionally, the association between the model predictions and prognosis was further analyzed.

resultsFemale sex, and albumin and bilirubin concentrations were identified as risk factors, and a nomogram was built based on these factors. The areas under the ROC curves of the training and validation groups were 0.809 and 0.791, respectively. Moreover, calibration curves showed that predictions of the nomogram had good concordance with the actual outcomes. The correlation analysis demonstrated that PBC patients with a high probability of a suboptimal biochemical response were more likely to have adverse outcomes.

conclusionWe constructed a nomogram, which can accurately predict the risk of inadequate biochemical response to UDCA, facilitating the early screening of high-risk patients with PBC who should be prioritized for additional therapy.

Indexed as

Liver Cirrhosis, BiliaryNomogramsAdultDisease ProgressionFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisRisk FactorsTreatment OutcomeUrsodeoxycholic AcidUrsodeoxycholic Acidautoimmune liver diseasebiochemical responsenomogramprimary biliary cholangitisursodeoxycholic acid

Identifiers

PMID32915500
PMCPMC7676192
OpenAlexW3085074700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.